Source-grounded facts extracted from ACHIEVE LIFE SCIENCES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Reid Waldman was appointed as Director at ACHIEVE LIFE SCIENCES, INC..
“the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date.”
Jeff Farrow was appointed as Director at ACHIEVE LIFE SCIENCES, INC..
“the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date.”
ACHIEVE LIFE SCIENCES, INC. reported the three months ended March 31, 2026 results: net income $10.2 million.
“Total operating expenses and net loss for the three months ended March 31, 2026 were $10.5 million and $10.2 million, respectively”
ACHIEVE LIFE SCIENCES, INC. reported financial results for the first quarter of 2026.
“today announced financial results for the first quarter of 2026”
ACHIEVE LIFE SCIENCES, INC. reported financial results for the first quarter ended March 31, 2026.
“On May 12, 2026, Achieve Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
Jaime Xinos departed as Chief Commercial Officer at ACHIEVE LIFE SCIENCES, INC..
“Jaime Xinos, the Company’s Chief Commercial Officer, will depart the Company, effective as of May 31, 2026.”
Lucian Iancovici was appointed as Chair of the Board at ACHIEVE LIFE SCIENCES, INC..
“Lucian Iancovici, MD, was appointed as Chair of the Board, effective as of June 8, 2026.”
Thomas King resigned as Chairman of the Board and Member at ACHIEVE LIFE SCIENCES, INC..
“Thomas King informed the Board that he has elected to resign from his position as a member and as chairman of the Board, effective as of June 8, 2026.”
Christopher Martin was appointed as Director at ACHIEVE LIFE SCIENCES, INC..
“appointed Christopher Martin to serve as a director of the Company, effective immediately.”
ACHIEVE LIFE SCIENCES, INC. issued 49,418,069 shares of common stock to institutional and accredited investors for $3.635 per combination of Shares and accompanying Common Warrants.
“aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock"), and, in lieu of Shares for an Investor, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 100,500 shares of Common Stock (the “Pre-Funded Warrant Shares”), and (ii) accompanying warrants (the “Common Warrants”) to purchase up to 49,518,569 shares of Common Stock or pre-funded warrants to purchase Common Stock (the “Common Warrant Shares,” and together with the Shares, Pre-Funded Warrant Shares, Pre-Funded Warrants and the Common Warrants, the “Securities”) at a collective purchase price of (a) $3.635 per combination of Shares and accompanying Common Warrants”
ACHIEVE LIFE SCIENCES, INC. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $180.0 million (effective 2026-04-15).
“On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock”
ACHIEVE LIFE SCIENCES, INC. reported the fourth quarter and full year ended December 31, 2025 results: net income Total net loss for the three and twelve months ended December 31, 2025, was $14.7 million and $54.7 million, respectivel.
“On March 24, 2026, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”
Kristen B. Slaoui was appointed as Director at ACHIEVE LIFE SCIENCES, INC..
“On January 6, 2025, the Board appointed each of Nancy R. Phelan and Kristen B. Slaoui, Ph.D. (together, the “Incoming Directors”) to serve as a director of the Company, effective January 6, 2025.”
Nancy R. Phelan was appointed as Director at ACHIEVE LIFE SCIENCES, INC..
“On January 6, 2025, the Board appointed each of Nancy R. Phelan and Kristen B. Slaoui, Ph.D. (together, the “Incoming Directors”) to serve as a director of the Company, effective January 6, 2025.”
Vaughn Himes resigned as Director at ACHIEVE LIFE SCIENCES, INC..
“On January 6, 2025, Dr. Vaughn Himes informed the board of directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”), that he has elected to resign from his position as a member of the Board, effective immediately.”
Richard Stewart was appointed as Chief Executive Officer at ACHIEVE LIFE SCIENCES, INC..
“the Board of Directors of the Company (the “ Board ”) appointed Richard Stewart as the Company’s Chief Executive Officer, “principal executive officer” and “principal financial officer.””
John Bencich resigned as Chief Executive Officer at ACHIEVE LIFE SCIENCES, INC..
“determined that John Bencich will no longer serve as the Company’s Chief Executive Officer, “principal executive officer” or “principal financial officer,” effective as of August 21, 2024”
ACHIEVE LIFE SCIENCES, INC. reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
ACHIEVE LIFE SCIENCES, INC. reported fourth quarter and year ended December 31, 2023 results: net income $5.5 million and $29.8 million.
“Total net loss for the fourth quarter and year ended December 31, 2023 was $5.5 million and $29.8 million, respectively.”
ACHIEVE LIFE SCIENCES, INC. terminated At-the-Market Sales Agreement with Virtu Americas LLC valued at Termination of at-the-market offering program (effective 2024-02-28).
“Item 1.02 Termination of Material Definitive Agreement As previously disclosed, on December 21, 2021, the Company entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with Virtu Americas LLC (“Virtu”) with respect to an “at-the-market” offering program under which the Company could offer and sell, from time to time at the Company’s sole discretion, shares of Common Stock through Virtu as its sales agent.”
ACHIEVE LIFE SCIENCES, INC. entered into Securities Purchase Agreement with Purchasers valued at up to 13,086,151 shares at $4.585 per share and warrants (effective 2024-02-28).
“On February 28, 2024, Achieve Life Sciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain purchasers (the “Purchasers”) for the sale of up to 13,086,151 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.585 per Share.”
ACHIEVE LIFE SCIENCES, INC. reported third quarter 2023 results: net income Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively..
“Total net loss for the three and nine months ended September 30, 2023 was $7.1 million and $24.3 million, respectively.”
ACHIEVE LIFE SCIENCES, INC. reported second quarter of 2023 results: revenue $25.1 million, net income $8.2 million.
“terminated in connection with the new contingent convertible debt agreement. Financial Results As of June 30, 2023, the company’s cash, cash equivalents, and restricted cash was $25.1 million. Total operating expenses for the three and six months ended June 30, 2023 were $7.7 million and $16.3 million, respectively. Total net loss for the three and six months ended”
ACHIEVE LIFE SCIENCES, INC.: Third Amended and Restated Certificate of Incorporation filed to permit exculpation of officers under Delaware law (effective 2023-06-08).
“On June 8, 2023, the Company filed the Third Amended and Restated Certificate of Incorporation with the Delaware Secretary of State to effect such amendment.”
ACHIEVE LIFE SCIENCES, INC. shareholders approved Approval of the Company’s 2023 Non-Employee Director Equity Incentive Plan at the 2023-06-07 meeting.
“Approval of the Company’s 2023 Non-Employee Director Equity Incentive Plan: For Against Abstain Broker Non-votes 8,373,952 897,609 171,205 4,581,301 Pursuant to the foregoing votes, the Company’s 2023 Non-Employee Director Equity Incentive Plan is approved.”
ACHIEVE LIFE SCIENCES, INC. shareholders approved Approval, by a non-binding advisory vote, of whether future non-binding advisory votes to approve the compensation paid by the Company to its named executive officers should be held every one, two or three years at the 2023-06-07 meeting.
“Approval, by a non-binding advisory vote, of whether future non-binding advisory votes to approve the compensation paid by the Company to its named executive officers should be held every one, two or three years: 1 Year 2 Years 3 Years Abstain 1,968,627 327,350 7,119,074 27,715 Pursuant to the foregoing non-binding advisory votes, the stockholders approved the frequency for future advisory votes on compensation paid by the Company to its named executive officers of every three years. Consistent with the recommendation of the Company’s Board of Directors and the outcome of the stockholder vote regarding this proposal, the Company’s Board of Directors determined to hold an advisory vote once every three years to approve the compensation paid by the Company to its named executive officers.”
ACHIEVE LIFE SCIENCES, INC. shareholders approved Approval, by a non-binding advisory vote, of the compensation paid by the Company to its named executive officers at the 2023-06-07 meeting.
“Approval, by a non-binding advisory vote, of the compensation paid by the Company to its named executive officers: For Against Abstain Broker Non-votes 8,705,275 554,973 182,518 4,581,301 Pursuant to the foregoing non-binding advisory votes, the compensation paid by the Company to its named executive offices is approved.”
ACHIEVE LIFE SCIENCES, INC. shareholders approved Approval of an amendment and restatement of the Company’s Second Amended and Restated Certificate of Incorporation to permit the exculpation of officers as permitted pursuant to recent amendments to the Delaware General Corporation Law at the 2023-06-07 meeting.
“Approval of an amendment and restatement of the Company’s Second Amended and Restated Certificate of Incorporation to permit the exculpation of officers as permitted pursuant to recent amendments to the Delaware General Corporation Law: For Against Abstain Broker Non-votes 9,243,103 162,071 37,592 4,581,301 Pursuant to the foregoing votes, the amendment and restatement of the Company’s Second Amended and Restated Certificate of Incorporation is approved.”
ACHIEVE LIFE SCIENCES, INC. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
“Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain Broker Non-votes 13,913,542 92,933 17,592 — Pursuant to the foregoing votes, the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified.”
ACHIEVE LIFE SCIENCES, INC. shareholders approved Election of eight directors to serve until the Company’s next annual meeting or until the directors’ successors are duly elected and qualified at the 2023-06-07 meeting.
“Election of eight directors to serve until the Company’s next annual meeting or until the directors’ successors are duly elected and qualified: For Withhold Broker Non-Votes John Bencich 8,969,977 472,789 4,581,301 Stuart Duty 9,328,630 114,136 4,581,301 Vaughn Himes 9,328,424 114,342 4,581,301 Cindy Jacobs 8,918,432 524,334 4,581,301 Thomas B. King 9,330,635 112,131 4,581,301 Bridget Martell 8,926,207 516,559 4,581,301 Thomas Sellig 9,331,568 111,198 4,581,301 Richard Stewart 8,808,167 634,599 4,581,301 Pursuant to the foregoing votes, the nominees listed above were elected as directors to serve on the Company’s board of directors.”
ACHIEVE LIFE SCIENCES, INC. entered into Securities Purchase Agreement with certain purchasers valued at 3,000,000 shares at $5.50 per share, gross proceeds approximately $16.5 million (effective 2023-05-25).
“On May 25, 2023, Achieve Life Sciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the sale of 3,000,000 shares (the “Shares”) of the Company’s common stock at a price of $5.50 per share, for gross proceeds of approximately $16.5 million before deducting the placement fees and related offering expenses.”
ACHIEVE LIFE SCIENCES, INC. incurred term loan of aggregate original principal amount of $16.56 million with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P., as lenders at floating rate per annum equal to the greater of (i) 2.25% and (ii) the prime rat maturing December 22, 2024, subject to acceleration upon failure to receive FDA filing communication by certain dates.
“On May 15, 2023, Achieve Life Sciences, Inc. (“ Achieve ”) entered into a contingent convertible debt agreement (the “ Debt Agreement ”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“ FCB ”), in its capacity as administrative agent and collateral agent (in such capacity, the “ Agent ”), FCB, as a lender, SVB Innovation Credit Fund VIII, L.P., as a lender (“ Innovation ”), and Innovation Credit Fund VIII-A, L.P., as a lender (together with FCB and Innovation, the “ Lenders ”), pursuant to which the Lenders provided term loans having an aggregate original principal amount of $16.56 million (the “ Convertible Term Loan ”).”
ACHIEVE LIFE SCIENCES, INC. entered into Debt Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as administrative agent and collateral agent, and the Lenders (SVB Innovation Credit Fund VIII, L.P., and Innovation Credit Fund VIII-A, L.P.) valued at $16.56 million (effective 2023-05-15).
“On May 15, 2023, Achieve Life Sciences, Inc. (“ Achieve ”) entered into a contingent convertible debt agreement (the “ Debt Agreement ”) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“ FCB ”), in its capacity as administrative agent and collateral agent (in such capacity, the “ Agent ”), FCB, as a lender, SVB Innovation Credit Fund VIII, L.P., as a lender (“ Innovation ”), and Innovation Credit Fund VIII-A, L.P., as a lender (together with FCB and Innovation, the “ Lenders ”), pursuant to which the Lenders provided term loans having an aggregate original principal amount of $16.56 million (the “ Convertible Term Loan ”).”
ACHIEVE LIFE SCIENCES, INC. reported the first quarter ended March 31, 2023 results: net income $9.0 million.
“Total net loss for the first quarter ended March 31, 2023 was $9.0 million.”
Jay Moyes departed as Director at ACHIEVE LIFE SCIENCES, INC..
“Mr. Donald Joseph, Dr. Martin Mattingly and Mr. Jay Moyes (collectively, the “Outgoing Directors”), each a member of the Board, informed the Board that they would not be standing for reelection to the Board when their terms end at the Company’s 2023 annual meeting”
Martin Mattingly departed as Director at ACHIEVE LIFE SCIENCES, INC..
“Mr. Donald Joseph, Dr. Martin Mattingly and Mr. Jay Moyes (collectively, the “Outgoing Directors”), each a member of the Board, informed the Board that they would not be standing for reelection to the Board when their terms end at the Company’s 2023 annual meeting”
Donald Joseph departed as Director at ACHIEVE LIFE SCIENCES, INC..
“Mr. Donald Joseph, Dr. Martin Mattingly and Mr. Jay Moyes (collectively, the “Outgoing Directors”), each a member of the Board, informed the Board that they would not be standing for reelection to the Board when their terms end at the Company’s 2023 annual meeting”
ACHIEVE LIFE SCIENCES, INC. amended Amendment to Cooperation Agreement with Dialectic Capital Management, LP and related entities (effective 2023-03-21).
“On March 21, 2023, Achieve Life Sciences, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its Cooperation Agreement (the “Cooperation Agreement”) with Dialectic Capital Management, LP (“Dialectic”) and related entities (collectively with Dialectic, the “Stockholders”) regarding certain changes to the composition of the Company’s board of directors (the “Board”) and other related matters.”
ACHIEVE LIFE SCIENCES, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 22, 2022, Achieve Life Sciences, Inc., a Delaware corporation (the “ Company ”), received a written notification from the Listing Qualifications staff of The Nasdaq Stock Market (“ Nasdaq ”) that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million (the “ Stockholders’ Equity Requirement ”). The Company’s Form 10-Q for the quarter ended September 30, 2022, filed on November 14, 2022, reflect”
ACHIEVE LIFE SCIENCES, INC. entered into Registration Rights Agreement with the Purchasers (effective 2022-11-18).
“Pursuant to the Subscription Agreements, on November 18, 2022, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”) with the Purchasers, under which the Company is required to file a registration statement within 60 days following the final closing date of the Offering (the “ Registration Statement ”).”
ACHIEVE LIFE SCIENCES, INC. entered into Placement Agent Agreement with Lake Street Capital Markets, LLC.
“Lake Street Capital Markets, LLC (the “ Placement Agent ”), acted as the exclusive placement agent for the Offering and, pursuant to the engagement agreement between the Company and the Placement Agent (the “ Placement Agent Agreement ”), will receive a cash commission equal to 5% of the gross proceeds from the sale of the Units.”
ACHIEVE LIFE SCIENCES, INC. entered into Subscription Agreements with certain accredited investors valued at approximately $18.9 million (effective 2022-11-14).
“On November 14, 2022, Achieve Life Sciences, Inc., a Delaware corporation (the “ Company ”), entered into subscription agreements (the “ Subscription Agreements ”) with certain accredited investors (the “ Purchasers ”) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement 4,093,141 units (each, a “ Unit ”), each consisting of (i) two shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and (ii) a warrant to purchase one share of Common Stock (the “ Warrants ”), at an offering price of $4.625 per Unit, for aggregate gross proceeds of approximately $18.9 million (the “ Offering ”).”
ACHIEVE LIFE SCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income $13.1 million.
“Total net loss for the three and nine months ended September 30, 2022 was $13.1 million and $31.1 million, respectively.”
Vaughn Himes was appointed as director at ACHIEVE LIFE SCIENCES, INC..
“the Board of Directors (the “ Board ”) of Achieve Life Sciences, Inc. (the “ Company ”) appointed Vaughn Himes, PhD., as a director, effective March 14, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.